To order this
detailed 250+ page report, please visit this link
Key Inclusions
§
A detailed review of the overall landscape of companies
offering contract manufacturing services for biopharmaceuticals in China, along
with information on year of establishment, company size, scale of operation
(preclinical, clinical and commercial), location of headquarters, number of
manufacturing facilities, as well as location of these facilities, type of
business segment, type of manufacturing service(s) offered (process development
and characterization, method validation and testing, analytical development, stability
studies, quality assurance and control, scale-up, downstream processing,
regulatory support, data analytics and reporting, and others), type of
biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell
therapies, gene therapies, antibody drug conjugates, vectors, biosimilars,
nucleic acids and others), type of expression system(s) used (mammalian,
microbial and others), type of bioreactor(s) used (single-use bioreactors and
stainless steel bioreactors) and its mode of operation (batch, fed-batch and
perfusion), type of packaging, and affiliations to regulatory accreditations
and certifications (if any).
§
An analysis of the various partnerships pertaining to
biopharmaceutical manufacturing in China, which have been established since 2016,
based on several parameters, such as the year of partnership, type of
partnership model adopted, scale of operation, type of biologic, focus area of
the deal, target indication, most active players (in terms of number of
partnerships signed), and geography.
§
An analysis of the various expansion initiatives undertaken
by contract manufacturers in China, in order to augment their capabilities,
over the period 2016-2020 (till February), taking into consideration several
relevant parameters, such as year of expansion, type of expansion (capability
expansion, capacity expansion, facility expansion and new facility), scale of
operation of manufacturing facility, type of biologic and location of
manufacturing facility.
§
A clinical trial analysis of completed and active studies
related to biopharmaceuticals that have been / are being / are likely to be
conducted in China, based on trial registration year, trial phase, trial
recruitment status, type of sponsor / collaborator, geography and number of
patients enrolled.
§
An estimate of the overall, installed capacity for
manufacturing biopharmaceuticals, based on data reported by industry
stakeholders in the public domain; it highlights the distribution of available
biopharmaceutical production capacity on the basis of company size (small,
mid-sized, large and very large firms), scale of operation (preclinical,
clinical and commercial), key geographical regions (China, Hong-Kong, Taiwan)
and expression system used.
§
A review of recent initiatives undertaken by big pharma
players in China for the manufacturing of biopharmaceuticals, highlighting
trends across various parameters, such as number of initiatives, year of
initiative, and benchmark analysis of big pharma players.
§
A qualitative analysis, highlighting the various factors
that need to be taken into consideration by drug / therapy developers while
deciding whether to manufacture their respective products in-house or engage
the services of a CMO.
§
Elaborate profiles of key players that have a diverse range
of capabilities for the development, manufacturing and packaging of
biopharmaceutical products. Each profile features an overview of the company,
its financial performance (if available), information on its service portfolio,
details related to manufacturing capabilities and facilities, recent
developments (partnerships and expansions), and an informed future outlook.
§
A case study comparing the key characteristics of large
molecule and small molecule drugs, along with details on the various steps
involved in their respective manufacturing processes.
§
A discussion on industry affiliated trends, key drivers and
challenges, under a SWOT framework, which are likely to impact the evolution of
this field. It also includes a Harvey ball analysis, highlighting the relative
impact of each SWOT parameter on industry dynamics.
The
report also features the likely distribution of the current and forecasted
opportunity across important market segments, mentioned below:
§
API
§
FDF
- Type
of Expression System Used
§
Mammalian
§
Microbial
§
Others
§
Preclinical /
Clinical
§
Commercial
§
Small
§
Mid-sized
§
Large / Very Large
§
Antibody
§
Vaccine
§
Others
To request sample
pages, please visit this link
Key Questions
Answered
§
Who are the leading biopharmaceutical contract manufacturers
in China?
§
What is the annual clinical demand for biopharmaceuticals
in China?
§
What is the current installed capacity for manufacturing
biopharmaceuticals in China?
§
What kind of partnership models are commonly adopted by
stakeholders engaged in this domain?
§
What were the various expansion initiatives carried out by
Chinese biopharmaceutical CMOs?
§
What were the different biopharmaceutical focused
initiatives undertaken by big pharma players in the recent past, in China?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be interested in the following
titles:
1. China Pharmaceutical
Contract Manufacturing Services Market, 2020-2030
2.
Live Biotherapeutics
Products and Microbiome Contract Manufacturing Market: Focus on Active
Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
3.
Oligonucleotide
Synthesis, Modification and Purification Services Market: Focus on Research,
Diagnostic and Therapeutic Applications, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com